Praha, Czechoslovakia

Hana Dvorakova


Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 134(Granted Patents)


Location History:

  • Prague, CZ (1992)
  • Praha, CZ (2000)

Company Filing History:


Years Active: 1992-2000

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Hana Dvorakova

Introduction

Hana Dvorakova is a prominent inventor based in Praha, Czech Republic. She has made significant contributions to the field of antiviral pharmaceutical compositions, particularly through her innovative patents. With a total of 2 patents, her work has been instrumental in advancing treatments for retroviral infections.

Latest Patents

Dvorakova's latest patents include groundbreaking inventions such as antiretroviral enantiomeric nucleotide analogs. These resolved enantiomers are useful in antiviral pharmaceutical compositions aimed at treating retroviral infections. Another notable invention is the compound (2R)-2-[di(2-propyl)phosphonylmethoxy]-3-p-toluenesulfonyloxy-1-trimethylacetoxypropane. This compound can be utilized for producing (S)-N-(3-hydroxy-2-phosphonylmethoxypropyl) derivatives of heterocyclic purine and pyrimidine bases, which exhibit antiviral activity.

Career Highlights

Throughout her career, Dvorakova has worked with esteemed institutions such as the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences and Rega Stichting. Her research has focused on developing innovative solutions to combat viral infections, showcasing her dedication to improving public health.

Collaborations

Dvorakova has collaborated with notable professionals in her field, including Antonin Holy and Erik Desire DeClercq. These partnerships have further enhanced her research and contributed to the success of her inventions.

Conclusion

Hana Dvorakova's contributions to antiviral research and her innovative patents highlight her role as a leading inventor in the pharmaceutical field. Her work continues to inspire advancements in the treatment of retroviral infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…